jefferies' michael yee on biogen as fda could be on the verge of approving alzheimer's drug
Published 1 year ago • 1.5K plays • Length 3:46Download video MP4
Download video MP3
Similar videos
-
14:26
$iova amtagvi keytruda clinical trial (com-202) readout beat the current melanoma treatment standard
-
6:51
the volatility of the vix has picked substantially, says rbc's amy wu silverman
-
6:15
iova stock | why the biology says it could revolutionize medicine!
-
3:33
jefferies' michael yee still likes amgen in the biotech sector
-
10:12
why is the stock down after fda approval? what's next? iova stock - iovance analysis
-
6:48
if you invest in communism in the long run, you'll lose every time: hayman capital's kyle bass
-
15:59
blackrock ceo larry fink on us economy, trump vs. harris, geopolitical risks (full interview)
-
4:47
port strike will push u.s. into a recession if it lasts more than a month: sea-intelligence ceo
-
2:57
jefferies' michael yee explains his top biotech picks: vrtx, fate, zlab
-
17:53
iovance biotherapeutics
-
3:01
biogen's alzheimer's drug is the biggest growth catalyst for the stock, says jefferies' yee
-
3:19
iovance ceo on its progress with a new cancer treatment for solid tumors
-
14:39
iovance biotherapeutics
-
5:12
abbvie to acquire neuroscience drugmaker cerevel therapeutics for $8.7 billion
-
14:41
iovance biotherapeutics
-
14:57
iovance biotherapeutics
-
16:40
iovance biotherapeutics
-
14:56
iovance biotherapeutics
-
2:52
iyph 2020 promotional video